Abivax SA Sponsored ADR ABVX 深 沪
等待开盘 03-26 09:30:00 美东时间
110.70
+0.530
+0.48%
华盛通- 最 高113.75
- 今 开112.00
- 成交量 78.19万股
- 最 低 110.13
- 昨 收 110.17
- 总市值 87.53亿
- 52周最高 148.83
- 市盈率 静 --
- 换手率 0.99%
- 52周最低 4.77
- 委 比 -19.37%
- 总股本 7907.26万
- 历史最高 148.83
- 量 比 0.57
- 振 幅 3.29%
- 历史最低 4.77
- 每 手 1
- 风险率 48.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears
Abivax plans fundraising after June trial data as CEO signals no urgency to sell amid takeover speculation and strong stock momentum.
03-25 01:53
Barclays Maintains Overweight on Abivax, Raises Price Target to $148
Barclays analyst Etzer Darout maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $142 to $148.
03-24 22:00
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell • Avalo Therapeutics (NASDAQ:AVTX) is likel...
03-23 19:11
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Abivax SA Sponsored ADR (ABVX) Initiated with a Buy at Leerink Partners
Leerink Partners analyst Faisal Khurshid initiated coverage with a Buy rating o...
03-16 08:36
'Abivax Denies French Media Report Of Astrazeneca Takeover' - CNBC
https://www.cnbc.com/2026/03/12/abivax-denies-astrazeneca-takeover-.html
03-12 23:02
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
AstraZeneca holds exclusive access to Abivax's data room until March 23 as Eli Lilly waits. Key Phase 3 trial results expected in June.
03-12 18:46
Why Petco Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Petco Health and Wellness (WOOF) reported strong Q4 sales, but missed earnings estimates. Other gainers include TLYS, LSF, CDXS, TURB, WGRX, BMBL, LWLG, ABVX, and BATL. Losers include NTSK, GSUN, VSA, and TANH.
03-12 17:28
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
